WASHINGTON (Reuters) – The U.S. Food and Drug Administration is aiming to give full approval to Pfizer’s COVID-19 vaccine on Monday, the New York Times reported on Friday.
Regulators had been working to finish the process by Friday, but were still working through “a substantial amount of paperwork and negotiation with the company,” the Times said, citing people familiar with the planning who were not authorized to speak publicly about it.
The agency had set an unofficial deadline for approval of around Labor Day, the newspaper said.
(Reporting by Katanga Johnson; Editing by Tim Ahmann)
